News
Cumulus Neuroscience begins studies of digital biomarker
Cumulus Neuroscience has announced the beginning of new clinical studies to investigate the company’s digital biomarker in quantifying cognitive decline over time, in patients with conditions such as dementia and Alzheimer’s disease.